Testosterone for Women and Weight Loss: What the Evidence Actually Shows

Testosterone isn't a weight-loss treatment for women. An international consensus endorsed by eleven medical societies supports it for one use only: low sexual desire that causes distress after menopause. No testosterone product is FDA-approved for women in the US. In trials, it did not reduce weight. If weight is the goal, GLP-1 medicines are the treatment with the evidence.

That may not match what you have seen in ads or heard from a hormone clinic. Below is what testosterone does in a woman's body, what the trials found on weight and body composition, who it can actually help, and where it fits next to a GLP-1.

What does testosterone do in women?

Women make testosterone too, in the ovaries and adrenal glands, at much lower levels than men. It plays a part in sexual desire, and the body can convert some of it into estradiol, a form of estrogen. Levels decline gradually across the reproductive years rather than dropping off a cliff at menopause¹.

There is no medical condition called "low testosterone" in women. The Endocrine Society's guideline recommends against diagnosing an androgen deficiency syndrome in healthy women, because no well-defined syndrome exists and blood levels have not been shown to line up with specific symptoms³. A blood level is used to check that treatment stays in a safe range, not to diagnose a problem. The consensus statement says the same for low desire: a blood testosterone level should not be used to diagnose it¹.

That matters because a common sales pitch starts with a hormone panel that shows a "low" number and a promise that raising it will fix fatigue, weight and mood. The major guidelines do not support that chain of reasoning.

Does testosterone help women lose weight or belly fat?

The best evidence says no. The 2019 meta-analysis that informed the global consensus pooled 36 randomized trials with 8,480 women. It found that testosterone improved several measures of sexual function, recorded an overall increase in weight with treatment, and found no effect on body composition². The number of women with body-composition data was small, but nothing in that pool points toward weight loss.

The consensus statement, written by an expert panel and endorsed by eleven societies including the Endocrine Society and The North American Menopause Society, reached the same conclusion: at doses that keep blood levels in the normal female range, testosterone had no significant effect on lean body mass, total body fat or muscle strength¹. The Endocrine Society's guideline goes further and recommends against general use of testosterone for metabolic health or general well-being³.

Sources for this table: the global consensus statement¹ and the meta-analysis behind it².

Why do some studies show more muscle?

Because they used more testosterone. In a 24-week trial of 71 women who had had a hysterectomy, weekly testosterone injections at four doses were compared with placebo. Lean body mass and some power measures improved, but only in the highest-dose group, where average testosterone reached about 210 ng/dL⁶, well above typical levels for women. In the same trial, the two higher doses measurably lowered the pitch of women's voices, a change tied directly to how high testosterone rose⁷.

That is the trade-off in plain terms. The doses that change body composition are the doses that start to masculinize. Guidelines ask clinicians to keep women in the premenopausal female range for exactly this reason, and at that range the body-composition effect largely disappears¹.

There is also a metabolic reason to be careful. In women, higher androgen levels tend to travel with insulin resistance and abdominal fat, not against them. That pattern is a core feature of PCOS, where excess androgens are part of the metabolic problem rather than a cure for it⁸. More testosterone is not a route to a leaner metabolism for most women.

What is testosterone approved or recommended for in women?

One thing: hypoactive sexual desire disorder (HSDD), meaning low sexual desire that causes personal distress, in postmenopausal women, diagnosed after a full assessment of other causes such as relationship stress, depression or medications¹. The benefit is real but modest; the consensus describes it as about one extra satisfying sexual event a month compared with placebo.

For premenopausal women, the consensus found insufficient data to recommend testosterone for sexual function or anything else¹. A later clinical practice guideline from the International Society for the Study of Women's Sexual Health noted limited data supporting use in late-reproductive-age women with HSDD, but it too recommends transdermal treatment at female doses, with monitoring, and only after other causes are addressed⁴.

In the US, no testosterone product is approved for women, so any prescription is off-label: either a male product used at a fraction of the dose, or a compounded cream⁵. The consensus recommends the first route over the second where an approved product exists, because compounded products have no efficacy or safety data¹⁴.

How is it prescribed safely?

If you and a clinician decide to try testosterone for low desire after menopause, the consensus describes what responsible care looks like¹:

The stop rule is worth holding a program to. If a provider plans to keep you on testosterone indefinitely without a clear benefit you can name, ask why.

What are the risks of testosterone for women?

At doses that stay in the female range, the side effects reported in trials are mostly mild: more acne and more body or facial hair in some women². The consensus found no clear link at those doses to hair loss, clitoral enlargement or voice change, and no serious adverse events in trials, but safety data at physiologic doses do not extend beyond about two years¹. Long-term data on heart disease, breast cancer and cognition are lacking⁵.

The larger risks come from how testosterone is often sold to women:

Pellets and injections. Both can push levels well above the female range, which is why the consensus advises against them¹⁵. Pellets are implanted under the skin and cannot be removed easily if side effects appear.

Compounded creams. Compounded products are not FDA-approved, and the FDA does not review compounded preparations for safety, quality or effectiveness⁹. Strength can vary between batches, which makes it harder to stay in a safe range.

Oral testosterone. It raises LDL cholesterol and lowers HDL, so it is not recommended¹².

Why do weight programs bundle testosterone with GLP-1s?

Several telehealth programs that sell GLP-1 medicines also sell a women's testosterone option in the same catalog, often next to estradiol and progesterone. Our reviews of Goldspan Health and NEUVÉ Health, for example, note a women's testosterone option alongside the weight program. Selling both in one place can be convenient if you already have a legitimate reason to use each. It does not mean testosterone adds to the weight loss. If a program presents testosterone as part of a weight plan, the evidence above is the question to ask them about.

If low desire after menopause is a real concern for you, testosterone is a reasonable conversation to have, separately from weight, with a clinician who will measure levels, use a transdermal female-range dose and stop it if it does not help.

What should you ask before starting testosterone?

If a clinic or telehealth program offers you testosterone, these questions separate careful care from a sales funnel. Each follows from the guidelines above.

A program that cannot answer the first question without mentioning weight, or that recommends pellets as a first choice, is selling something the evidence does not support¹³.

It also helps to be clear about what else might explain the symptoms that lead women to ask about testosterone. Low desire, fatigue and weight gain in midlife often have several overlapping causes: disrupted sleep from night sweats, mood changes, thyroid problems, medications such as some antidepressants, relationship stress and the hormonal shifts of perimenopause. The consensus asks for a full assessment of those before testosterone is considered for low desire¹, and they are worth looking at for their own sake too.

If weight is the goal, what works?

GLP-1 medicines have the evidence that testosterone lacks. In the STEP 1 trial, semaglutide 2.4 mg produced about 15% average weight loss over 68 weeks¹⁰. In SURMOUNT-1, tirzepatide produced up to about 20% at the highest dose¹¹. Both trials enrolled mostly women.

For midlife women, the questions that matter most on a GLP-1 are different ones: protecting muscle and bone while losing fat, and managing menopause symptoms alongside the medicine. Our guides to GLP-1s through perimenopause and menopause, muscle loss on GLP-1s and bone density on GLP-1s cover each. Strength training, adequate protein and, where appropriate, estrogen-based menopause hormone therapy are the levers with evidence for body composition in this stage of life.

To compare programs, our menopause GLP-1 board lines up telehealth programs on how well they suit women in the transition, and CoreAge Rx, a featured partner, offers both semaglutide and tirzepatide nationwide. If PCOS is part of your picture, see how to lose weight with PCOS.

We earn a commission when you start treatment through some links on this site, at no extra cost to you. CoreAge Rx is a featured partner, and providers we work with may appear first. Educational content, not medical advice. Talk to a licensed clinician before starting any treatment.